Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors (ProFEIBA)
A Prospective, Randomized, Cross-over Study of an Activated Prothrombin Complex Concentrate for Secondary Prophylaxis in Patients With Hemophilia A and Inhibitors
Sponsor: Tulane University School of Medicine
Listed as NCT00221195, this PHASE2/PHASE3 trial focuses on Hemophilia A With Inhibitors and remains completed. Sponsored by Tulane University School of Medicine, it has been updated 8 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2_PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Apr 2020 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
Status: Unknown Status → Completed
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Jun 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tulane University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .